ProCE Banner Activity

DeLLphi-300: Updated Data From Phase I Study of Tarlatamab, a DLL3-Targeted T-Cell Engager, in Relapsed/Refractory SCLC

Slideset Download
Conference Coverage
Tarlatamab showed promising antitumor activity with durable responses and an acceptable safety profile for patients with relapsed/refractory SCLC after multiple lines of therapy.

Released: August 12, 2022

Expiration: August 11, 2023

No longer available for credit.


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from

Amgen, Inc.

Genentech, a member of the Roche Group

Merck Sharp & Dohme Corp.

Turning Point Therapeutics Inc